About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment

NCT07472270·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Thanh Liem Nguyen
CONTACT
(+84) 98 656 50 15 v.liemnt@vinmec.com
Van T. Hoang
CONTACT
+84 93 644 94 81

Lead

Vinmec Research Institute of Stem Cell and Gene Technology

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Liver cirrhosis due to alcohol-related liver disease or chronic hepatitis B or C
Child-Pugh score 7-12
Alcohol-related cirrhosis: abstinent from alcohol ≥ 3 months
HBV/HCV-related cirrhosis: viral disease controlled according to standard clinical criteria
Written informed consent provided

You may not be if

Significant renal dysfunction or coagulation abnormalities
Liver cirrhosis of unknown etiology
Current or suspected hepatocellular carcinoma or history of malignancy
Portal vein thrombosis
Pregnancy, breastfeeding, or inadequate contraception
Severe renal, respiratory, cardiovascular, infectious, autoimmune, metabolic, or neurological disorders that may interfere with study participation
Refractory ascites at screening
Use of known hepatotoxic medications within a clinically relevant period
Coinfection with HIV, tuberculosis, or other causes of chronic liver disease

The record

StatusNot yet recruiting

PhasePhase 1

Taking part12

StartedMar 2026

UpdatedMar 16, 2026

Conditions

Liver Cirrhosis

Where1

Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Vietnam